Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.7K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

From dose to exposure? rethinking fluoropyrimidines as immune checkpoint partners in gastrointestinal cancers.

Current opinion in oncology·2026
Same author

Left Atrial Appendage Occlusion Versus Direct Oral Anticoagulation in Atrial Fibrillation Patients at Very High Risk of Stroke: A Budget Impact Analysis in Italy.

Journal of clinical medicine·2026
Same author

Efficacy of buparlisib according to PIK3CA mutation status in recurrent or metastatic head and neck squamous cell carcinoma: A multicenter phase II trial.

Oral oncology·2026
Same author

Evolution of bispecific and multispecific antibodies in cancer therapy.

The Lancet regional health. Europe·2026
Same author

A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumours.

European journal of cancer (Oxford, England : 1990)·2026

Related Experiment Video

Updated: Dec 11, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.6K

Targeting molecular subtypes in solid cancers: successes and failures.

Rita Assi1, Nuria Kotecki2, Ahmad Awada2

  • 1Department of Internal Medicine, Division of Hematology-Oncology, Lebanese American University Medical Center, Rizk Hospital, Beyrouth, Lebanon.

Current Opinion in Oncology
|August 16, 2020
PubMed
Summary

Drug resistance is a major challenge in targeted cancer therapies. Understanding resistance patterns is key to developing new strategies for solid tumors.

More Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.4K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.5K

Related Experiment Videos

Last Updated: Dec 11, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.6K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.4K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.5K

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Targeted therapies have revolutionized cancer treatment over the last two decades.
  • The efficacy of targeted agents is often limited by the development of intrinsic or acquired drug resistance.
  • Mechanisms of resistance include phenotypic switching, pathway evasion, poor drug selectivity, delivery issues, and high costs.

Purpose of the Study:

  • To review major resistance patterns observed with earlier targeted therapies.
  • To extract key lessons learned from the application of these therapies in solid tumors.
  • To highlight the challenges hindering the success of targeted cancer treatments.

Main Methods:

  • Review of existing literature on targeted therapies in solid tumors.
  • Analysis of documented mechanisms of drug resistance.
  • Identification of patterns in treatment failures.

Main Results:

  • Drug resistance is an inevitable consequence of targeted therapy, involving complex molecular and cellular adaptive mechanisms.
  • Tumor plasticity and phenotypic switching contribute significantly to acquired resistance.
  • Failures are also attributed to factors beyond molecular resistance, including drug delivery and cost.

Conclusions:

  • Collaborative efforts are underway to design improved targeted drugs and combination strategies.
  • Development of sensitive assays is crucial for monitoring treatment response and detecting emerging resistance.
  • Addressing resistance mechanisms is essential for advancing the clinical utility of targeted cancer therapies.